Avi BioPharma
Recent developments from Avi BioPharma highlighted
Published in Pharma Investments, Ventures and Law Weekly, December 31st, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Avi BioPharma.
Report 1: Avi BioPharma, Inc., (AVII) presented data and analysis from four Neugene antisense clinical studies at the second annual meeting of the Oligonucleotide Therapeutics Society at Rockefeller University in New York.
The studies showed that Avi-4557 inhibited the metabolic enzyme cytochrome P450 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently marketed drugs.
The clinical briefing, titled...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Alcohol Use
Alcohol monitor achieves milestones in fight against alcohol abuse - Business Update
MedCom subsidiary Card Activation Technologies sends additional license agreement requests - Business Update
NDSI Healthcare, Sandata to integrate home health software and telephony technology - Business Update
Tenet reaches partial settlement with IRS, expects to make $80 million payment in Q4 2006 - Facilities
Bunker Hill Community College to build new health and wellness center - Finance
LCA-Vision completes share repurchase plan, announces new share plan, increases dividend - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
